{
    "clinical_study": {
        "@rank": "33500", 
        "arm_group": [
            {
                "arm_group_label": "Silybin - vitamin E - phospholipids complex", 
                "arm_group_type": "Active Comparator", 
                "description": "Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill for 12 months."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "sugar pill"
            }
        ], 
        "brief_summary": {
            "textblock": "Background: Hepatitis C virus infection and interferon treatment have shown to be risk\n      factors for depression, distressing, psychosocial burden and poor health-related quality of\n      life.\n\n      Aim: To determine the effect of a Sylibin-vitamin E-phoshpolipids complex on work ability\n      and whether health related factors (anxiety and depression) were associated with work\n      ability in subjects with chronic hepatitis C treated with Peg-IFN-\u03b1 and RBV.\n\n      Patients and Methods: In this prospective, randomized, placebo controlled, double blind\n      clinical trial, 31 subjects (Group A) with chronic hepatitis, received\n      Pegylated-Interferon-\u03b12b (1.5 mg/kg per week) plus Ribavirin and placebo, while 31 subjects\n      (Group B) received the same dosage of  Pegylated-Interferon-\u03b12b plus Ribavirin plus\n      association of Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill for 12\n      months. All subjects underwent laboratory exams and questionnaires to evaluate depression\n      (Beck Depression Inventory - BDI), anxiety (State-trait anxiety inventory - STAI) and work\n      ability (Work ability Index - WAI)."
        }, 
        "brief_title": "Silybin Supplementation During HCV Therapy With Pegylated Interferon-\u03b12b Plus Ribavirin Reduces Depression and Increases Work Ability", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Work Ability", 
            "Depression"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HCV infection\n\n        Exclusion Criteria:\n\n          -  cancer severe jaundice pulmonary and renal chronic diseases prostatic diseases\n             autoimmune diseases diabetes mellitus decompensated cirrhosis pregnancy\n             hemoglobinopathies hemocromatosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01957319", 
            "org_study_id": "12/1997"
        }, 
        "intervention": [
            {
                "arm_group_label": "Silybin - vitamin E - phospholipids complex", 
                "intervention_name": "Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "sugar pill", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferons", 
                "Ribavirin", 
                "Vitamin E", 
                "Alpha-Tocopherol", 
                "Tocopherols", 
                "Tocotrienols", 
                "Silybin", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Catania", 
                    "country": "Italy", 
                    "zip": "95125"
                }, 
                "name": "University of Catania, Cannizzaro Hospital"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Silybin Supplementation During HCV Therapy With Pegylated Interferon-\u03b12b Plus Ribavirin Reduces Depression and Increases Work Ability", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Administration of questionnaire(Work ability Index - WAI)The work ability index is a tool to record the work ability of employees. It aims at identifying, at an early stage, health risks of early retirement an counteracting them. The questionnaire is aimed at: 1) the estimated current and future work ability; 2) diagnosed illness and the number of absenteeism days in the previous year; 3) the estimated sickness-related deterioration in the work performance; 4) mental ability reserves.  The WAI evaluates current work ability compared with lifetime and in relation to the demands of the job, number of current diseases diagnosed by a physician, estimated work impairment due to diseases.", 
            "measure": "Work ability index", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957319"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Catania", 
            "investigator_full_name": "Mariano Malaguarnera", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "depression", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "source": "University of Catania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Catania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}